Logo image of MSGS

MADISON SQUARE GARDEN SPORTS (MSGS) Stock Fundamental Analysis

USA - NYSE:MSGS - US55825T1034 - Common Stock

223.55 USD
+1.63 (+0.73%)
Last: 9/26/2025, 8:13:50 PM
223.55 USD
0 (0%)
After Hours: 9/26/2025, 8:13:50 PM
Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to MSGS. MSGS was compared to 80 industry peers in the Entertainment industry. MSGS has a bad profitability rating. Also its financial health evaluation is rather negative. MSGS is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

3

1. Profitability

1.1 Basic Checks

In the past year MSGS has reported negative net income.
In the past year MSGS had a positive cash flow from operations.
In multiple years MSGS reported negative net income over the last 5 years.
Of the past 5 years MSGS 4 years had a positive operating cash flow.
MSGS Yearly Net Income VS EBIT VS OCF VS FCFMSGS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 100M -100M 200M -200M -300M

1.2 Ratios

MSGS has a Return On Assets (-1.52%) which is in line with its industry peers.
MSGS has a Return On Invested Capital of 1.25%. This is in the better half of the industry: MSGS outperforms 61.25% of its industry peers.
MSGS had an Average Return On Invested Capital over the past 3 years of 7.74%. This is in line with the industry average of 9.25%.
The 3 year average ROIC (7.74%) for MSGS is well above the current ROIC(1.25%). The reason for the recent decline needs to be investigated.
Industry RankSector Rank
ROA -1.52%
ROE N/A
ROIC 1.25%
ROA(3y)2.11%
ROA(5y)1.84%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)7.74%
ROIC(5y)N/A
MSGS Yearly ROA, ROE, ROICMSGS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20 -20 40 60 80

1.3 Margins

MSGS has a Operating Margin (1.42%) which is in line with its industry peers.
MSGS's Operating Margin has declined in the last couple of years.
With a Gross Margin value of 33.84%, MSGS is not doing good in the industry: 60.00% of the companies in the same industry are doing better.
MSGS's Gross Margin has declined in the last couple of years.
Industry RankSector Rank
OM 1.42%
PM (TTM) N/A
GM 33.84%
OM growth 3Y-48.58%
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-10.62%
GM growth 5Y-3.48%
MSGS Yearly Profit, Operating, Gross MarginsMSGS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20 -20 40

3

2. Health

2.1 Basic Checks

The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so MSGS is destroying value.
Compared to 1 year ago, MSGS has more shares outstanding
Compared to 5 years ago, MSGS has about the same amount of shares outstanding.
Compared to 1 year ago, MSGS has an improved debt to assets ratio.
MSGS Yearly Shares OutstandingMSGS Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 5M 10M 15M 20M
MSGS Yearly Total Debt VS Total AssetsMSGS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 1B 2B 3B

2.2 Solvency

MSGS has an Altman-Z score of 2.18. This is not the best score and indicates that MSGS is in the grey zone with still only limited risk for bankruptcy at the moment.
MSGS has a better Altman-Z score (2.18) than 66.25% of its industry peers.
The Debt to FCF ratio of MSGS is 3.31, which is a good value as it means it would take MSGS, 3.31 years of fcf income to pay off all of its debts.
MSGS has a Debt to FCF ratio of 3.31. This is in the better half of the industry: MSGS outperforms 77.50% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF 3.31
Altman-Z 2.18
ROIC/WACC0.15
WACC8.58%
MSGS Yearly LT Debt VS Equity VS FCFMSGS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 500M 1B 1.5B 2B 2.5B

2.3 Liquidity

MSGS has a Current Ratio of 0.45. This is a bad value and indicates that MSGS is not financially healthy enough and could expect problems in meeting its short term obligations.
MSGS has a Current ratio of 0.45. This is amonst the worse of the industry: MSGS underperforms 80.00% of its industry peers.
A Quick Ratio of 0.45 indicates that MSGS may have some problems paying its short term obligations.
The Quick ratio of MSGS (0.45) is worse than 78.75% of its industry peers.
Industry RankSector Rank
Current Ratio 0.45
Quick Ratio 0.45
MSGS Yearly Current Assets VS Current LiabilitesMSGS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 500M 1B 1.5B

4

3. Growth

3.1 Past

The earnings per share for MSGS have decreased strongly by -137.86% in the last year.
The Revenue has been growing slightly by 1.18% in the past year.
Measured over the past years, MSGS shows a quite strong growth in Revenue. The Revenue has been growing by 11.49% on average per year.
EPS 1Y (TTM)-137.86%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-106.6%
Revenue 1Y (TTM)1.18%
Revenue growth 3Y8.16%
Revenue growth 5Y11.49%
Sales Q2Q%-10.25%

3.2 Future

MSGS is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 24.82% yearly.
Based on estimates for the next years, MSGS will show a small growth in Revenue. The Revenue will grow by 3.19% on average per year.
EPS Next Y54.27%
EPS Next 2Y43.27%
EPS Next 3Y24.82%
EPS Next 5YN/A
Revenue Next Year0.89%
Revenue Next 2Y2.87%
Revenue Next 3Y3.19%
Revenue Next 5YN/A

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
MSGS Yearly Revenue VS EstimatesMSGS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 500M 1B 1.5B
MSGS Yearly EPS VS EstimatesMSGS Yearly EPS VS EstimatesYearly EPS VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 0 2 -2 4 -4 6 -6

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for MSGS. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for MSGS. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
MSGS Price Earnings VS Forward Price EarningsMSGS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 -100 -200 -300 -400 -500

4.2 Price Multiples

Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of MSGS is on the same level as its industry peers.
MSGS's Price/Free Cash Flow ratio is in line with the industry average.
Industry RankSector Rank
P/FCF 61.03
EV/EBITDA 302.5
MSGS Per share dataMSGS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 20 -20 40

4.3 Compensation for Growth

MSGS's earnings are expected to grow with 24.82% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y43.27%
EPS Next 3Y24.82%

0

5. Dividend

5.1 Amount

No dividends for MSGS!.
Industry RankSector Rank
Dividend Yield N/A

MADISON SQUARE GARDEN SPORTS

NYSE:MSGS (9/26/2025, 8:13:50 PM)

After market: 223.55 0 (0%)

223.55

+1.63 (+0.73%)

Chartmill FA Rating
GICS IndustryGroupMedia & Entertainment
GICS IndustryEntertainment
Earnings (Last)08-12 2025-08-12/bmo
Earnings (Next)10-30 2025-10-30/bmo
Inst Owners77.11%
Inst Owner ChangeN/A
Ins Owners2.39%
Ins Owner Change6.03%
Market Cap5.37B
Analysts80
Price Target256.83 (14.89%)
Short Float %5.08%
Short Ratio4.48
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly Dividend0.03
Dividend Growth(5Y)N/A
DP-2.82%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-50.91%
Min EPS beat(2)-141.27%
Max EPS beat(2)39.44%
EPS beat(4)2
Avg EPS beat(4)-30.23%
Min EPS beat(4)-141.27%
Max EPS beat(4)64.86%
EPS beat(8)5
Avg EPS beat(8)9.74%
EPS beat(12)7
Avg EPS beat(12)-6.54%
EPS beat(16)9
Avg EPS beat(16)15.93%
Revenue beat(2)1
Avg Revenue beat(2)13.16%
Min Revenue beat(2)-3.05%
Max Revenue beat(2)29.38%
Revenue beat(4)2
Avg Revenue beat(4)11.36%
Min Revenue beat(4)-3.05%
Max Revenue beat(4)29.38%
Revenue beat(8)5
Avg Revenue beat(8)18.35%
Revenue beat(12)9
Avg Revenue beat(12)14.8%
Revenue beat(16)10
Avg Revenue beat(16)12.59%
PT rev (1m)2.03%
PT rev (3m)3%
EPS NQ rev (1m)-12.75%
EPS NQ rev (3m)-13.59%
EPS NY rev (1m)0%
EPS NY rev (3m)-125.24%
Revenue NQ rev (1m)-1.41%
Revenue NQ rev (3m)-16.73%
Revenue NY rev (1m)-0.49%
Revenue NY rev (3m)-3.31%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 5.17
P/FCF 61.03
P/OCF 58.62
P/B N/A
P/tB N/A
EV/EBITDA 302.5
EPS(TTM)-0.92
EYN/A
EPS(NY)-0.42
Fwd EYN/A
FCF(TTM)3.66
FCFY1.64%
OCF(TTM)3.81
OCFY1.71%
SpS43.26
BVpS-11.72
TBVpS-25.46
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -1.52%
ROE N/A
ROCE 1.63%
ROIC 1.25%
ROICexc 1.48%
ROICexgc 2.55%
OM 1.42%
PM (TTM) N/A
GM 33.84%
FCFM 8.47%
ROA(3y)2.11%
ROA(5y)1.84%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)7.74%
ROIC(5y)N/A
ROICexc(3y)8.5%
ROICexc(5y)N/A
ROICexgc(3y)14.98%
ROICexgc(5y)N/A
ROCE(3y)10.02%
ROCE(5y)N/A
ROICexcg growth 3Y-45.45%
ROICexcg growth 5YN/A
ROICexc growth 3Y-44.77%
ROICexc growth 5YN/A
OM growth 3Y-48.58%
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-10.62%
GM growth 5Y-3.48%
F-Score4
Asset Turnover0.71
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF 3.31
Debt/EBITDA 16.14
Cap/Depr 112.52%
Cap/Sales 0.35%
Interest Coverage 250
Cash Conversion 508.19%
Profit Quality N/A
Current Ratio 0.45
Quick Ratio 0.45
Altman-Z 2.18
F-Score4
WACC8.58%
ROIC/WACC0.15
Cap/Depr(3y)91.68%
Cap/Depr(5y)60.4%
Cap/Sales(3y)0.32%
Cap/Sales(5y)0.24%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-137.86%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-106.6%
EPS Next Y54.27%
EPS Next 2Y43.27%
EPS Next 3Y24.82%
EPS Next 5YN/A
Revenue 1Y (TTM)1.18%
Revenue growth 3Y8.16%
Revenue growth 5Y11.49%
Sales Q2Q%-10.25%
Revenue Next Year0.89%
Revenue Next 2Y2.87%
Revenue Next 3Y3.19%
Revenue Next 5YN/A
EBIT growth 1Y-89.85%
EBIT growth 3Y-44.39%
EBIT growth 5YN/A
EBIT Next Year112.25%
EBIT Next 3Y-30.01%
EBIT Next 5YN/A
FCF growth 1Y-2.97%
FCF growth 3Y-20.81%
FCF growth 5YN/A
OCF growth 1Y-0.57%
OCF growth 3Y-19.88%
OCF growth 5Y91.04%